Although our cohort was not enriched in bi-allelic BRCA1/2 alterations, the HRD scoring measurement has the ability to identify additional patients, beyond BRCA deficiency, with high sensitivity to platinum agents or PARP inhibitors27. This evidence concerns the gene BRCA1 and hyperinsulinemic hypoglycemia, familial, 4.